https://www.benzinga.com/general/biotech/22/01/25128078/liminal-biosciences-pauses-development-of-fezagepras-outlines-r-d-priorities-for-2022
Liminal BioSciences Pauses Development Of Fezagepras, Outlines R&D Priorities For 2022 - Benzinga
Jan 20, 2022 - Following the analysis of the preliminary pharmacokinetic data from the Phase I MAD trial, Liminal BioSciences Inc (NASDAQ: LMNL) said that it